0001415889-24-021194.txt : 20240813 0001415889-24-021194.hdr.sgml : 20240813 20240813170005 ACCESSION NUMBER: 0001415889-24-021194 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240812 FILED AS OF DATE: 20240813 DATE AS OF CHANGE: 20240813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ferguson Matthew CENTRAL INDEX KEY: 0001304079 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39577 FILM NUMBER: 241202665 MAIL ADDRESS: STREET 1: C/O FOXHOLLOW TECHNOLOGIES, INC. STREET 2: 740 BAY ROAD CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ELUTIA INC. CENTRAL INDEX KEY: 0001708527 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474790334 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12510 PROSPERITY DRIVE STREET 2: SUITE 370 CITY: SILVER SPRING STATE: MD ZIP: 20904 BUSINESS PHONE: 240-247-1143 MAIL ADDRESS: STREET 1: 12510 PROSPERITY DRIVE STREET 2: SUITE 370 CITY: SILVER SPRING STATE: MD ZIP: 20904 FORMER COMPANY: FORMER CONFORMED NAME: AZIYO BIOLOGICS, INC. DATE OF NAME CHANGE: 20170605 4 1 form4-08132024_050801.xml X0508 4 2024-08-12 0001708527 ELUTIA INC. ELUT 0001304079 Ferguson Matthew C/O ELUTIA INC. 12510 PROSPERITY DRIVE, SUITE 370 SILVER SPRING MD 20904 false true false false CHIEF FINANCIAL OFFICER 0 Class A Common Stock 2024-08-12 4 M 0 50000 A 307823 D Class A Common Stock 2024-08-12 4 F 0 17840 2.84 D 289983 D Restricted Stock Units 2024-08-12 4 M 0 50000 0 D Class A Common Stock 50000 0 D Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units. On January 31, 2024, the Reporting Person was granted 50,000 restricted stock units. The restricted stock units vested on the 10th business day following the clearance by the U.S. Food & Drug Administration ("FDA") of the Company's CanGarooRM antibiotic-eluting biologic envelope, unless such date is not during one of the Company's open trading windows, in which case such RSUs vested as of the first business day of the next open trading window. The CanGarooRM antibiotic-eluting biologic envelope, now known as EluPro, was cleared by the FDA on June 14, 2024 and the first business day of the next open trading window was August 12, 2024. /s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson 2024-08-13